NCT05526924 2026-03-04
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
Clinical Trials
9 trialsNCT07026474 2026-03-02
RePaIr-HN
Universität des Saarlandes
Phase 3 Recruiting
NCT06557889 2026-02-11
REDUCE
Institut Claudius Regaud
Phase 2 Recruiting
NCT06699212 2025-10-15
ECLIPSE
Rakuten Medical, Inc.
Phase 3 Recruiting
NCT05446467 2025-08-20
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
Zhejiang Provincial People's Hospital
Phase 2 Recruiting
NCT06943820 2025-06-03
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
Phase 1/2 Recruiting
NCT05125055 2023-11-22
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Shanghai Jiao Tong University School of Medicine
Phase 2/3 Recruiting
NCT06102395 2023-10-30
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Beijing Tongren Hospital
Phase 3 Recruiting
NCT05862168 2023-07-17
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
Zhejiang University
Phase 2 Recruiting